NCT00226005View on ClinicalTrials.gov

PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

February 28, 2010

Conditions
Neoplasm
Interventions
DRUG

PTK787/ZK222584

One arm: administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.

Trial Locations (7)

21231

Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins, Baltimore

37203

Sarah Cannon Research Institute, Nashville

55407

Virginia Piper Cancer Institute/Abbott Northwestern Hospital, Minneapolis

78229

South Texas Oncology and Hematology, San Antonio

85259

Scottsdale Healthcare, Scottsdale

85724

University of Arizona/Arizona Cancer Center, Tucson

90211-18500

Tower Hematology Oncology Medical Group, Beverly Hills

All Listed Sponsors
lead

Pancreatic Cancer Research Team

OTHER

NCT00226005 - PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma | Biotech Hunter | Biotech Hunter